Trial Profile
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs Dilpacimab (Primary) ; Budigalimab; Fluorouracil; Folinic acid; Irinotecan; Paclitaxel
- Indications Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 13 Oct 2022 Status changed from active, no longer recruiting to completed.
- 23 Mar 2022 Planned End Date changed from 30 Oct 2023 to 26 Sep 2023.
- 23 Mar 2022 Planned primary completion date changed from 30 Oct 2023 to 26 Sep 2023.